Carestream Molecular Imaging, OncoVision sign exclusive agreement for Albira PET/SPECT/CT imaging system

Carestream Molecular Imaging, a division of Carestream Health, Inc., has signed an exclusive, multi-year worldwide agreement with OncoVision (Valencia, Spain), to sell, market and service the Albira PET/SPECT/CT imaging system for small animal research. With the addition of this innovative, multimodal imaging system, Carestream Molecular Imaging will offer the broadest portfolio of pre-clinical in vivo imaging modalities in the market. The system will be introduced at the American Association of Cancer Research (AACR) Annual Meeting in Washington, D.C., April 18-21.

“Albira offers unprecedented sensitivity and resolution allowing scientists to visualize metabolic processes and structures in small living animals. It is the technology of the future made reality now”

The Albira system features a modular architecture that introduces a patented single-crystal detector and associated electronics for rapid acquisition and reconstruction of highly resolved quantitative PET and SPECT images. This approach contrasts with the pixelated crystal technology used in most current PET and SPECT systems today.

"Albira offers unprecedented sensitivity and resolution allowing scientists to visualize metabolic processes and structures in small living animals. It is the technology of the future made reality now," said J. M. Benlloch, Ph.D., the founder of OncoVision and Professor, Superior Council of Scientific Research, Valencia, Spain.

Albira's advanced multimodal imaging technology is designed for pre-clinical researchers in academic, government, pharmaceutical, biotechnology and independent medical laboratories. With this new technology, scientists will advance their research into developing new predictive imaging biomarkers, accelerate the preclinical validation of new drugs, and enable the selection of drug candidates for clinical translation. Ultimately this will help speed up the drug discovery process.

"With the addition of the Albira system, in combination with Carestream Molecular Imaging's high-resolution optical and X-ray systems, we now offer the global research community the most innovative and extensive imaging product portfolio in the market. We are very excited about our new partnership with OncoVision and the innovation that we bring to the market today, and what lies ahead in the future," said John Dellisanti, President, Carestream Molecular Imaging.

Features and benefits include:

• High resolution, precise quantification and superior image quality through patented continuous crystal technology and electronics, and is enabled from a major advance in DOI performance, overcoming parallax error.
• Fast multimodal image acquisition and reconstruction, through a combination of proprietary electronics and optimized reconstruction algorithms and protocols, increases experimental throughput and compresses imaging workflow.
• Convenient automatic image fusion and precise co-registration of functional PET or SPECT images with anatomical CT images, all within the same instrument.
• User friendly, modular, state-of-the-art software suite for acquisition, reconstruction, management, and quality control. PMOD software included for volume of interest and kinetic analysis.
• Modular and upgradeable system configurations. Albira is offered as standalone PET, SPECT, or CT; bi-modal PET/CT or SPECT/CT; or tri-modal system—all within the same compact footprint.

SOURCE Carestream Molecular Imaging